Day One Biopharmaceuticals (NASDAQ:DAWN) Insider Sells $74,182.00 in Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Adam Dubow sold 6,395 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $74,182.00. Following the sale, the insider owned 72,694 shares of the company’s stock, valued at $843,250.40. The trade was a 8.09% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Day One Biopharmaceuticals Stock Down 2.4%

Shares of DAWN stock opened at $11.78 on Friday. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -7.75 and a beta of -1.26. Day One Biopharmaceuticals, Inc. has a fifty-two week low of $5.64 and a fifty-two week high of $13.20. The firm’s 50 day moving average price is $10.48 and its two-hundred day moving average price is $8.63.

Wall Street Analysts Forecast Growth

Several research analysts have commented on DAWN shares. Piper Sandler raised their price objective on Day One Biopharmaceuticals from $25.00 to $26.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. Zacks Research raised Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 26th. JPMorgan Chase & Co. lifted their price objective on shares of Day One Biopharmaceuticals from $26.00 to $27.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of Day One Biopharmaceuticals in a research report on Monday, November 24th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 price target on shares of Day One Biopharmaceuticals in a report on Monday, November 24th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $25.71.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Rubric Capital Management LP acquired a new stake in shares of Day One Biopharmaceuticals during the third quarter worth approximately $23,808,000. Vestal Point Capital LP grew its stake in Day One Biopharmaceuticals by 94.4% in the fourth quarter. Vestal Point Capital LP now owns 5,200,000 shares of the company’s stock worth $48,464,000 after purchasing an additional 2,525,000 shares in the last quarter. AIGH Capital Management LLC bought a new position in Day One Biopharmaceuticals during the 3rd quarter worth approximately $10,719,000. Mak Capital One LLC acquired a new position in shares of Day One Biopharmaceuticals in the 3rd quarter worth approximately $10,212,000. Finally, Balyasny Asset Management L.P. bought a new stake in shares of Day One Biopharmaceuticals in the 3rd quarter valued at approximately $9,758,000. 87.95% of the stock is owned by institutional investors and hedge funds.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.